secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000950170-23-039843
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Q2 net loss $17.5M; cash $303.3M; Nasdaq compliance regained
------------------------------------------------------------------

- Net loss of $17.5M for Q2 2023 vs. $16.9M in Q2 2022; R&D expense $14.9M, G&A $6.9M.
- Cash, cash equivalents & short-term investments of $303.3M at June 30, 2023; July offering raised ~$60M gross.
- PSMA-TRACTr JANX007 Phase 1 data showed meaningful PSA drops with manageable safety/CRS profile.
- Nasdaq compliance regained after Ron Barrett, Ph.D. became independent director; matter closed.
- Appointed Dr. Zachariah McIver as VP, Clinical Development; he brings >15 years bispecific experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017023039843/0000950170-23-039843-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017023039843/janx-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039843

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer